Menopause Hormone Therapy Cuts Bone-Weakening Risk by 69%
New data presented at ENDO 2026 show postmenopausal women using hormonal therapy have about a 69% lower risk of low bone mineral density in the spine and hip than nonusers, with findings holding after adjusting for age, menopause duration, vitamin D, smoking and other factors. While HRT can ease symptoms and reduce fractures, clinicians still weigh cancer risks and typical usage limits (seven years for estrogen alone, three to five years for estrogen-progestin).
